FOR GREATER STABILITY

HGCO19 will be a lyophilized (freeze-dried) MRNA vaccine

MRNA vaccines typically require sub-zero temperatures to remain stable

Before administration, Gennova’s vaccine will be reconstituted by using diluents

Gennova has got permission for phase-2 and 3 trials

Pfizer and Biontech are also testing lyophilized formulation